Despite the weakness in the Sensex and Nifty on Thursday, some stocks completely ignored the market pressure. One such stock is Senores Pharmaceuticals, which comes from the small-cap pharma space. Following the company's b quarterly results, the stock has seen a tremendous surge. The stock rose up to 16% during trading today and touched a new yearly high.
Double Profit and Strong Income Jump
Senores Pharmaceuticals recently released its first quarter results for fiscal year 2026. The company reported that its consolidated profit increased from ₹10.9 crore to ₹21.2 crore. That is, the profit almost doubled on an annual basis. Not only profit, but the company's income also saw a growth of 72 percent. In the first quarter, the company's total income was ₹138 crore, which was ₹80.4 crore in the same quarter last year.
The company's quarterly performance also recorded a strengthening of 60 percent in EBITDA (Earnings Before Interest, Tax, Depreciation, and Amortization). The company management says that they have achieved this performance due to new generic drug orders and export growth.
Management's Confidence Increased
After the quarterly results, the company stated that they have entered into several new agreements in the US and European markets. Also, the demand for medicines is increasing rapidly in Latin America and Asia. Due to this, the company expects that growth will continue in the coming quarters as well.
The company also says that the new product portfolio and the expansion of the API (Active Pharmaceutical Ingredient) plant will also improve operating margins in the coming months. In addition, the company's manufacturing units have recently received several international accreditations as well.
Share Made a New Record of the Year
Senores Pharmaceuticals' stock reached ₹704.90 during trading today with a gain of 16%, which is the stock's highest level of the year. The stock's previous closing price was ₹609.75, while today it closed with a gain of 12 percent in intraday trading.
If we compare from the beginning of this year, in January 2025 this stock was trading around ₹440. That is, in just six months, the stock has jumped about 60 percent.
Brokerage Houses Showed Confidence
Some mid-size brokerage firms have presented a positive outlook on this stock. They believe that if the company continues to maintain its growth in the same way, then even better returns can be seen in the coming quarters.
The brokerage report also stated that Senores' emphasis on R&D and its strategy of launching products in regulated markets like the US and Europe sets it apart from other pharma companies.
Stir in the Pharma Sector
Apart from Senores Pharmaceuticals, some other pharma companies also saw a slight increase in today's session. Especially small-cap and mid-cap pharma companies, which are showing strength in execution and profits, are getting a good response from the market.
Some traders say that this trend in the pharma sector may continue for the time being because healthcare expenditures are continuously increasing and global demand also remains b.
What does the Trading Volume say?
In today's trading session, Senores' volume was also much higher than normal. On the BSE, the stock's volume was almost 3 times higher than the average of the last 10 days, which shows that active buying is being seen in the market regarding this stock.
Eyes Now on the Next Quarter
Now the market's eyes are fixed on the company's next quarter. Investors will want to see whether Senores Pharmaceuticals is able to maintain this pace or not. For the time being, it is clear from the stock's movement and volume after the results that the market has taken these numbers positively.
